To use all functions of this page, please activate cookies in your browser.
With an accout for my.chemeurope.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
- My watch list
- My saved searches
- My saved topics
- My newsletter
Bimatoprost (sold in the U.S. and Canada by Allergan, under the trade name Lumigan) is a prostamide used topically (as eye drops) to control the progression of glaucoma and in the management of ocular hypertension. It reduces intraocular pressure (IOP) by increasing the outflow of aqueous fluid from the eyes. It has also been used and prescribed off-label to lengthen eyelashes.
Additional recommended knowledge
In patients using ophthalmic prostaglandins such as travoprost and latanoprost, as well as prostamides like bimatoprost, it has been anecdotally noted that they have grown long and lush eyelashes. Allergan has initiated clinical trials investigating the usage of Lumigan as a cosmetic drug.
Several cosmetics companies have released products based on a prostaglandin analogs, as non-drug cosmetics.
These companies have been sued by Allergan for patent infringment. The FDA has seized Age Intervention Eyelash as an "unapproved and misbranded drug" because Jan Marini Skin Research promoted it as something that increases eyelash growth and because it is "adulterated" with bimatoprost.
Lumigan is a 0.03% solution of bimatoprost, and contains benzalkonium chloride as a preservative. Contact lenses should therefore be removed before use, and replaced no less than 15 minutes later; other eye drops or ointments should be given no less than 5 minutes before or after bimatoprost. It is administered once daily.
Possible side effects of this medication are:
On November 19 2007 the FDA issued a warning that bimatoprost is associated with optic nerve damage. This warning was delivered by their spokesperson during the seizure of a bimatoprost-containing cosmetic. Such warnings have not been issued for the prostaglandin analog derivatives, and may be specific to bimatoprost and the prostamide family.
|This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Bimatoprost". A list of authors is available in Wikipedia.|